Neurotech advances NTI164 with strong clinical data and new leadership

August 31, 2025 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Neurotech International (ASX: NTI) has reported a year of significant clinical achievements, regulatory recognition, and corporate renewal as it advances its proprietary cannabinoid therapy, NTI164, for paediatric neurological disorders. …

Subscribe now to continue reading.

Latest Video

Is the institution able to change in response to something it may not be capable of recognising?
September 28, 2025 - Latest News
Lower than expected uptake of new therapies impacts PBS spend
September 29, 2025 - Latest News
Mark Butler announces PBS listings for 1 October
September 28, 2025 - Latest News
Another blow for Australians with severe dermatitis as PBS falters again
September 28, 2025 - Latest News
The symptoms have been identified, but the widely held belief about the cause is a miss
September 30, 2025 - Latest News

Neurotech advances NTI164 with strong clinical data and new leadership

This is a preview of subscriber content

Latest Video

Most Read

Is the institution able to change in response to something it may not be capable of recognising?

Lower than expected uptake of new therapies impacts PBS spend

Mark Butler announces PBS listings for 1 October

Another blow for Australians with severe dermatitis as PBS falters again

The symptoms have been identified, but the widely held belief about the cause is a miss

New Stories

The symptoms have been identified, but the widely held belief about the cause is a miss

UK companies are granted more time to decide on pricing agreement

Anatara strengthens board with the appointment of Dirk van Dissel

CLINUVEL advances next-generation peptide drug formulations

Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy

Lower than expected uptake of new therapies impacts PBS spend

Chimeric reports encouraging early data from CHM CDH17 trial

Sign In

Neurotech advances NTI164 with strong clinical data and new leadership

This is a preview of subscriber content

Latest Video

Most Read

Is the institution able to change in response to something it may not be capable of recognising?

Lower than expected uptake of new therapies impacts PBS spend

Mark Butler announces PBS listings for 1 October

Another blow for Australians with severe dermatitis as PBS falters again

The symptoms have been identified, but the widely held belief about the cause is a miss

Follow Us

New Stories

The symptoms have been identified, but the widely held belief about the cause is a miss

UK companies are granted more time to decide on pricing agreement

Anatara strengthens board with the appointment of Dirk van Dissel

CLINUVEL advances next-generation peptide drug formulations

Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy

Lower than expected uptake of new therapies impacts PBS spend

Chimeric reports encouraging early data from CHM CDH17 trial